HC Wainwright Reaffirms “Buy” Rating for Halozyme Therapeutics (NASDAQ:HALO)

HC Wainwright reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a report published on Wednesday,Benzinga reports. HC Wainwright currently has a $68.00 price target on the biopharmaceutical company’s stock.

HALO has been the topic of a number of other reports. TD Cowen upped their target price on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Piper Sandler raised their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. JMP Securities boosted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Finally, Morgan Stanley boosted their price objective on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Stock Up 2.1 %

Shares of HALO opened at $45.76 on Wednesday. Halozyme Therapeutics has a 12 month low of $33.15 and a 12 month high of $65.53. The company has a 50-day moving average price of $55.15 and a two-hundred day moving average price of $53.48. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The stock has a market cap of $5.82 billion, a price-to-earnings ratio of 15.15, a P/E/G ratio of 0.41 and a beta of 1.29.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total transaction of $532,600.00. Following the completion of the sale, the senior vice president now owns 173,756 shares in the company, valued at $9,254,244.56. The trade was a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 60,000 shares of company stock worth $3,425,000 in the last quarter. Company insiders own 2.40% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Several large investors have recently bought and sold shares of HALO. GAMMA Investing LLC increased its stake in Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 254 shares during the last quarter. International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at $33,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at $49,000. Toth Financial Advisory Corp acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter worth $57,000. Finally, FSC Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the third quarter worth $65,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.